T he optimal management of carcinoma of the breast continues to undergo evolutionary changes and modification. Historically, radical mastectomy was replaced by modified radical mastectomy without negatively impacting outcomes. More recently, most general surgeons and surgical oncologists have adopted partial mastectomy with or without irradiation. Numerous comparative studies have demonstrated that breast conservation can be accomplished in most patients with breast cancer without placing patients at increased risk. The question concerning management of axillary lymph nodes has yet to be definitively answered. The case has been made that axillary dissection is unnecessary for most patients with breast cancer and serves as a staging procedure with little or no therapeutic benefit. Others have reported that approximately one third of patients undergoing axillary dissection for positive nodes is associated with an approximate 30% to 35% therapeutic efficacy. Some authors have suggested that early disease associated with favorable histopathology have such a low instance of nodal risk that they can be safely followed with very favorable long-term cure rates.
40 to 60% morbidity is most likely overstated. Silberman et al somewhat overstate the potential problems of sentinel node procedures relating to allergy to the dye and emphasize an unacceptable false negative rate. Collected data are now reaching maturity and indicate an exceedingly small failure associated with false negative sentinel node detection. The authors also overstate the risk associated with delaying adjuvant therapy dictated by the need for delayed axillary dissection for the patient population having positive sentinel nodes.
The data provided in the manuscript concerning the topic of lymphedema rely for the most part on circumferential measurements and patient-driven opinion. These types of data are vulnerable to subjective bias. A more accurate assessment of lymphedema has been shown to best be mea-sured by water displacement techniques. 3 It is highly unlikely that breast cancer management will revert to gold standards of the past. It is more likely that risk assessment in the near future will be dictated by genomics and microarray analyses.
